Table 1.
Patients’ clinical characteristics by cTACE and DEB-TACE groups. (N = 273)
| Variables | Total (N = 273) | cTACE (n = 201) | DEB-TACE (n = 72) | p-value |
|---|---|---|---|---|
| Age, years | 64.4 ± 10.7 | 65.3 ± 10.7 | 61.7 ± 10.3 | 0.009 |
| Sex | ||||
| Female | 86 (31.5) | 63 (31.3) | 23 (31.9) | 0.925 |
| Male | 187 (68.5) | 138 (68.7) | 49 (68.1) | |
| Previous treatment | ||||
| None | 172 (63.0) | 126 (62.7) | 46 (63.9) | 0.166 |
| Operation | 53 (19.4) | 35 (17.4) | 18 (25.0) | |
| Locoregional treatment | 41 (15.0) | 33 (16.4) | 8 (11.1) | |
| Operation + locoregional | 7 (2.6) | 7 (3.5) | 0 (0) | |
| Uni-/Bi-lobar | ||||
| Unilobar | 136 (49.8) | 106 (52.7) | 30 (41.7) | 0.107 |
| Bilobar | 137 (50.2) | 95 (47.3) | 42 (58.3) | |
| HBV/HCV | ||||
| Non-B or C | 22 (8.1) | 18 (9.0) | 4 (5.6) | 0.225 |
| HBV | 127 (46.5) | 87 (43.3) | 40 (55.6) | |
| HCV | 108 (39.6) | 82 (40.8) | 26 (36.1) | |
| HBV + HCV | 16 (5.9) | 14 (7.0) | 2 (2.8) | |
| GOT (IU/L) | 70.63 ± 48.72 | 69.88 ± 50.4 | 70.63 ± 48.72 | 0.331 |
| GOT | ||||
| Not normal | 156 (57.1) | 112 (55.7) | 44 (61.1) | 0.428 |
| Normal | 117 (42.9) | 89 (44.3) | 28 (38.9) | |
| GPT (IU/L) | 72.08 ± 80.27 | 69.97 ± 81.77 | 72.08 ± 80.27 | 0.109 |
| GPT | ||||
| Not normal | 132 (48.4) | 91 (45.3) | 41 (56.9) | 0.089 |
| Normal | 141 (51.6) | 110 (54.7) | 31 (43.1) | |
| Bilirubin (mg/dL) | 0.76 ± 0.44 | 0.73 ± 0.42 | 0.76 ± 0.44 | 0.087 |
| Bilirubin | ||||
| Not normal | 22 (8.1) | 13 (6.5) | 9 (12.5) | 0.107 |
| Normal | 251 (91.9) | 188 (93.5) | 63 (87.5) | |
| AFP (ng/mL) | 875.28 ± 4510.43 | 766.21 ± 4607.3 | 875.28 ± 4510.43 | 0.497 |
| AFP | ||||
| Negative | 224 (82.1) | 169 (84.1) | 55 (76.4) | 0.145 |
| Positive | 49 (17.9) | 32 (15.9) | 17 (23.6) | |
| Albumin (g/dL) | 4 ± 0.49 | 3.98 ± 0.48 | 4 ± 0.49 | 0.312 |
| Albumin | ||||
| Not normal | 41 (15.0) | 29 (14.4) | 12 (16.7) | 0.648 |
| Normal | 232 (85.0) | 172 (85.6) | 60 (83.3) | |
| Ascites | ||||
| None | 257 (94.1) | 191 (95.0) | 66 (91.7) | 0.432 |
| Mild | 15 (5.5) | 9 (4.5) | 6 (8.3) | |
| Moderate | 1 (0.4) | 1 (0.5) | 0 (0) | |
| Child-Pugh stage | ||||
| 5 | 219 (80.2) | 161 (80.1) | 58 (80.6) | 0.883 |
| 6 | 44 (16.1) | 33 (16.4) | 11 (15.3) | |
| 7 | 9 (3.3) | 6 (3.0) | 3 (4.1) | |
| 8 | 1 (0.4) | 1 (0.5) | 0 (0) | |
| ECOG stage | ||||
| 0 | 271 (99.3) | 199 (99.0) | 72 (100) | 1.000 |
| 1 | 2 (0.7) | 2 (1.0) | 0 (0) | |
| CLIP stage | ||||
| 0 | 40 (14.7) | 32 (15.9) | 8 (11.1) | 0.018 |
| 1 | 172 (63.0) | 132 (65.7) | 40 (55.6) | |
| 2 | 49 (17.9) | 29 (14.4) | 20 (27.8) | |
| 3 | 10 (3.7) | 8 (4.0) | 2 (2.8) | |
| 4 | 2 (0.7) | 0 (0) | 2 (2.8) | |
| Okuda stage | ||||
| 0 | 250 (91.6) | 185 (92.0) | 65 (90.3) | 0.471 |
| 1 | 20 (7.3) | 13 (6.5) | 7 (9.7) | |
| 2 | 3 (1.1) | 3 (1.5) | 0 (0) | |
| BCLC stage | ||||
| A | 87 (32) | 71 (35.7) | 16 (22.2) | 0.040 |
| B + C | 184 (67.9) | 128 (64.3) | 56 (77.8) | |
| Largest target (cm) | 3.64 ± 2.59 | 3.47 ± 2.32 | 4.12 ± 3.20 | 0.175 |
| Tumor numbers | 3.5 ± 1.9 | 3.4 ± 1.9 | 3.6 ± 2.0 | 0.690 |
| Tumor numbers ≤5 | 197 (72.2) | 148 (73.6) | 49 (68.1) | 0.365 |
| Tumor numbers > 5 | 76 (27.8) | 53 (26.4) | 23 (31.9) | |
| Sum of the largest five hepatocellular carcinoma diameter (cm) | 6.64 ± 2.33 | 6.63 ± 2.26 | 6.66 ± 2.53 | 0.908 |
Aspartate aminotransferase (GOT), Alanine aminotransferase (GPT)
Data are summarized as mean ± SD and n (%) for continuous and categorical variables by treatment. Differences between treatments were compared using Mann-Whitney U test for continuous variables and Chi-square test / or Fisher’s exact test for categorical variables
Bold p-values indicate statistical significance (p < 0.05)